Get the Stockscreener App
3.97
0.50%
-0.02
After Hours:
3.95
-0.02
-0.50%
Dermata Therapeutics Inc stock is traded at $3.97, with a volume of 30,184.
It is down -0.50% in the last 24 hours and down -28.85% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$3.99
Open:
$4
24h Volume:
30,184
Relative Volume:
0.25
Market Cap:
$2.71M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1854
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-4.34%
1M Performance:
-28.85%
6M Performance:
-45.54%
1Y Performance:
-74.87%
1-Day Range:
$3.914
$4.13
1-Week Range:
$3.83
$4.44
52-Week Range:
$3.83
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
3.97 | 2.72M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Technical analysis overview for Dermata Therapeutics Inc. Equity Warrant stockM&A Rumor & High Accuracy Swing Trade Signals - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock a top pick in earnings seasonBuy Signal & Low Drawdown Investment Ideas - Trung tâm Dự báo KTTV quốc gia
Market Outlook: How interest rate cuts could boost Dermata Therapeutics Inc. stock2025 Stock Rankings & Capital Efficiency Focused Ideas - Trung tâm Dự báo KTTV quốc gia
Short interest data insights for Dermata Therapeutics Inc. Equity WarrantJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
Chart overlay techniques for tracking Dermata Therapeutics Inc. Equity WarrantJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - newser.com
Analyzing Dermata Therapeutics Inc. Equity Warrant with risk reward ratio chartsJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Is Dermata Therapeutics Inc. Equity Warrant meeting your algorithmic filter criteriaPortfolio Risk Summary & High Win Rate Trade Tips - newser.com
Applying Elliott Wave Theory to Dermata Therapeutics Inc.2025 Market Overview & Technical Confirmation Alerts - newser.com
What analysts say about Dermata Therapeutics Inc Equity Warrant stockLarge Cap Stability Picks & Receive Monthly Expert Trading Blueprints - earlytimes.in
Analyzing drawdowns of Dermata Therapeutics Inc. with statistical toolsEarnings Trend Report & Weekly Stock Breakout Alerts - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock poised for growthJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Risk vs reward if holding onto Dermata Therapeutics Inc. Equity WarrantBreakout Watch & Advanced Swing Trade Entry Plans - newser.com
Can Expleo Solutions Limited Survive Disruption in Its Core IndustryREITs Market Trends & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
How buybacks impact Dermata Therapeutics Inc. Equity Warrant stock valueJuly 2025 Technicals & Fast Exit and Entry Trade Guides - newser.com
What valuation multiples suggest for Dermata Therapeutics Inc. Equity Warrant stockMarket Activity Recap & Daily Volume Surge Signals - newser.com
Why Dermata Therapeutics Inc. stock could outperform in 2025Weekly Investment Recap & Entry Point Confirmation Signals - newser.com
Advanced analytics toolkit walkthrough for Dermata Therapeutics Inc. Equity Warrant2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Momentum divergence signals in Dermata Therapeutics Inc. Equity Warrant chartEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
How to monitor Dermata Therapeutics Inc. Equity Warrant with trend dashboardsJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Developing predictive dashboards with Dermata Therapeutics Inc. dataJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Pattern recognition hints at Dermata Therapeutics Inc. upsideWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
Historical volatility pattern of Dermata Therapeutics Inc. visualizedPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Dermata Therapeutics announces $2.55M private offering - MSN
Using R and stats models for Dermata Therapeutics Inc. forecastingJuly 2025 Outlook & Short-Term High Return Ideas - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. Equity Warrant with statistical tools2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Does Dermata Therapeutics Inc. qualify in momentum factor screeningMarket Risk Analysis & Weekly High Potential Alerts - newser.com
Why Dermata Therapeutics Inc. stock remains a top recommendationJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Will Dermata Therapeutics Inc. Equity Warrant price bounce be sustainableEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
What drives Dermata Therapeutics Inc stock priceMarket Correction Analysis & Low Risk Investment Tips - earlytimes.in
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
News impact scoring models applied to Dermata Therapeutics Inc. Equity Warrant2025 Price Momentum & Smart Money Movement Tracker - newser.com
What the charts say about Dermata Therapeutics Inc. Equity Warrant today2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Why Dermata Therapeutics Inc. Equity Warrant stock is a must watch in 2025Market Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Measuring Dermata Therapeutics Inc. Equity Warrant’s beta against major indicesJuly 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
What momentum shifts mean for Dermata Therapeutics Inc. Equity WarrantWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com
Psyence Biomedical Stock Price, Quotes and Forecasts | NASDAQ:PBM - Benzinga
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):